Amol Akhade/hiranandanihospital.org
May 8, 2025, 22:33
Amol Akhade: Cmplete snapshot of Oral SERDs and PROTACs in ER+/HER2– mBC
Amol Akhade, Consultant Medical Oncologist at the Suyog Cancer Clinics, posted on X:
“Cmplete snapshot of Oral SERDs and PROTACs in ER+/HER2– mBC.
Phase 1–3 trials
Vepdegestrant: 2 trials halted
Elacestrant: still the only FDA-approved
New PROTACs: AC0682 (BBB+) and ZD12 (preclinical data )
All data in 1 slide.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 29, 2025, 14:15
May 29, 2025, 13:35
May 29, 2025, 13:11